EntreMed is a clinical-stage pharmaceutical company employing a drug development strategy primarily in the United States and China. Its lead compound, ENMD-2076, a selective angiogenic kinase inhibitor for the treatment of cancer. ENMD-2076 has completed several Phase 1 studies in solid tumors, multiple myeloma, and leukemia, is completing a multi-center Phase 2 study in ovarian cancer, and is currently enrolling for a dual-institution Phase 2 study in triple-negative breast trial.
Lead Drug Candidate
ENMD-2076 for Oncology. Our primary focus is the clinical development of our lead program, ENMD-2076. ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action. ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to the Aurora A kinase. Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers. ENMD-2076 also targets the VEGFR, Flt-3 and FGFR3 kinases which have been shown to play important roles in the pathology of several cancers. ENMD-2076 has shown promising activity in Phase 1 clinical trials in solid tumor cancers, leukemia, and multiple myeloma and in Phase 2 clinical trial for ovarian cancer.
Other Drug Candidates
Panzem® for Rheumatoid Arthritis and Multiple Sclerosis. Panzem® (2ME2) is an orally active compound that has anti-proliferative, anti-angiogenic and anti-inflammatory properties. Panzem® attacks tumor cells through multiple mechanisms of action including the inhibition of angiogenesis. Panzem® inhibits production of the transcription factor hypoxia inducible factor-1 alpha (HIF-1a), which is a protein required for angiogenesis and cell survival. The inhibition of angiogenesis is an important approach to the treatment of both cancer and rheumatoid arthritis. Panzem® has potential as a single agent in rheumatoid arthritis based on its anti-angiogenic, anti-inflammatory, anti-osteoclastic (bone resorption) properties. Panzem® has also shown positive preclinical results in multiple sclerosis.
MKC-1 for Oncology. MKC-1 is an orally-active, small molecule, cell cycle inhibitor with in vitro and in vivo efficacy against a broad range of human solid tumor cell lines, including multi-drug resistant cell lines. MKC-1 acts through multiple mechanisms of action, arresting cellular mitosis and inducing cell death (apoptosis) by binding to a number of different cellular proteins including tubulin and members of the importin B family. The company is seeking a partner to collaborate on further clinical investigation of MKC-1.